Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: TREND1, conix, Phaeton, $Pistol Pete$
Search This Board:
Last Post: 8/24/2016 9:27:49 PM - Followers: 354 - Board type: Free - Posts Today: 0


About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at:


Board of Directors

Alfred E. Mann

Alfred E. Mann has been one of our directors since April 1999, our Chairman of the Board since December 2001 and our Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio


Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge  A good forum for discussion on Mankind

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.;;




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MNKD News: Statement of Changes in Beneficial Ownership (4) 08/24/2016 06:44:57 PM
MNKD News: Statement of Changes in Beneficial Ownership (4) 08/24/2016 08:47:30 AM
MNKD News: Statement of Changes in Beneficial Ownership (4) 08/24/2016 08:45:19 AM
MNKD News: Statement of Changes in Beneficial Ownership (4) 08/24/2016 08:42:59 AM
MNKD News: Statement of Changes in Beneficial Ownership (4) 08/16/2016 07:57:09 AM
News News Alert: Statement of Changes in Beneficial Ownership (4) 08/24/2016 06:44:57 PM
#19569  Sticky Note $MNKD Charts Ready For The Reversal $Pistol Pete$ 08/24/16 08:19:48 PM
#19516  Sticky Note Nice blog article on MannKind. Phaeton 08/20/16 02:25:50 PM
#19573   I added a few at .88 as well.. lakingsphan0427 08/24/16 09:27:49 PM
#19572   $MNKD After hour closed at $.90. I think $Pistol Pete$ 08/24/16 09:20:26 PM
#19571   Agreed Go $MNKD $Pistol Pete$ 08/24/16 08:25:52 PM
#19570   nice closing MNKD mick 08/24/16 08:20:42 PM
#19569   $MNKD Charts Ready For The Reversal $Pistol Pete$ 08/24/16 08:19:48 PM
#19568   $MNKD lucky to get big at $.8523 $Pistol Pete$ 08/24/16 08:17:51 PM
#19567 mick 08/24/16 08:00:52 PM
#19566   Mike C another 15K shares and now has Hypi 08/24/16 07:57:24 PM
#19565   Good luck to you. As of today, I $Pistol Pete$ 08/24/16 05:03:23 PM
#19564   To late for that move as I'm up Hypi 08/24/16 04:46:20 PM
#19563   Yes Sir Go $MNKD $Pistol Pete$ 08/24/16 04:17:09 PM
#19562   good point. nasdaq down heavy today 50/ 'MannKind mick 08/24/16 03:57:49 PM
#19561   Trade them and don't marry them and it $Pistol Pete$ 08/24/16 02:39:26 PM
#19560   Stock market is so over valued that they Hypi 08/24/16 02:38:51 PM
#19559   Added some $.8523. Buying the dip and rip $Pistol Pete$ 08/24/16 02:35:32 PM
#19558   Ok its no longer my responsibility to support Hypi 08/24/16 02:09:49 PM
#19557   $MNKD nice accumulate Go $MNKD $Pistol Pete$ 08/24/16 01:57:46 PM
#19556   Re: Insulin Put exwannabe 08/24/16 01:55:37 PM
#19555 mick 08/24/16 01:48:11 PM
#19554   Well took on another 10K shares, so I Hypi 08/24/16 01:45:37 PM
#19553   MannKind Corporation, a development stage company, engages in mick 08/24/16 01:22:16 PM
#19552   I added some shares today for the reversal Go $MNKD $Pistol Pete$ 08/24/16 12:58:40 PM
#19551   $MNKD 15' Chart $Pistol Pete$ 08/24/16 12:57:42 PM
#19550 mick 08/24/16 12:57:12 PM
#19549   $MNKD MannKind (MNKD) CCO Castagna Buys Shares August 24, $Pistol Pete$ 08/24/16 12:56:32 PM
#19548   Nice and great to seeing you here Go $MNKD $Pistol Pete$ 08/24/16 12:51:44 PM
#19547   milestone paymeny ????? 2015 ????? 'MannKind Corp. (MNKD)' mick 08/24/16 12:51:17 PM
#19546   $MNKD BRIEF-Mannkind's cco Michael Castagna reports open market $Pistol Pete$ 08/24/16 12:41:44 PM
#19545   MNKD 4th quater story will really say it Denise Chanterelle 08/24/16 12:06:14 PM
#19544   Adding some shares here at $.90 today. Time $Pistol Pete$ 08/24/16 11:02:47 AM
#19543   Looking for some cash at the end of kugel 08/24/16 10:34:45 AM
#19542   You answered your own question. It's all Aloha96707 08/24/16 10:10:05 AM
#19541   What's going on right now with MNKD share Hypi 08/23/16 08:38:23 PM
#19540   Unfortunately time is not our friend, but I'm dinovix2778 08/23/16 04:40:33 PM
#19539   Show me the money. It is coming, buyout northandsouth1 08/23/16 12:15:20 AM
#19538   We expect that the third quarter of 2016 will be the final quarter of our profit WHS 08/22/16 11:28:53 PM
#19537   I'm not concerned right now because most physicians Hypi 08/22/16 08:15:49 PM
#19535   Payment refers to the "Insulin Put" that MNKD dinovix2778 08/22/16 05:00:54 PM
#19534   Unfortunately Matt looks like a liar. You're right, dinovix2778 08/22/16 04:59:15 PM
#19533   The good, the bad and the ugly. Hypi 08/22/16 03:42:01 PM
#19532   Do you see what i see?? potential everywhere.. kugel 08/22/16 01:48:02 PM
#19531   I agree, but I was just assuming that bakersson 08/22/16 12:53:14 PM
#19530   Interesting excerpt to this FAQ. Phaeton 08/22/16 12:34:48 PM
#19529   MannKind FAQ August 2016 just posted. Phaeton 08/22/16 12:33:31 PM
#19528   MannKind is working out their version on the Phaeton 08/22/16 12:29:03 PM
#19527   They price according to what the market will conix 08/22/16 11:19:07 AM
#19526   So why do we pay 10X and up Hypi 08/22/16 11:13:13 AM
#19525   The cost of a pharmaceutical and/or a medical conix 08/22/16 11:10:13 AM
#19521  Restored Does anyone know what is going on with bakersson 08/21/16 05:21:12 PM
#19520   $MNKD Daily Chart $Pistol Pete$ 08/21/16 03:46:36 PM